7.41
-2.11%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanxi C&Y Pharmaceutical Group Co
Its shares trade on Shenzhen under the ticker 300254.SZ. It has been listed since 19 August 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥870.8m and net income of CN¥24.9m. At that date it held total assets of CN¥1.64bn and shareholders' equity of CN¥304.6m.
Shanxi C&Y Pharmaceutical Group Co., Ltd. principally engages in the research, development, production, and sale of pharmaceuticals and supplements. The company is headquartered in Datong, Shanxi. The company went IPO on 2011-08-19. The Company’s main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. The company also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Aug 2011
- Employees
- 1,191
- Website
- cy-pharm.com ↗
Leadership
Pay as last reported
- Mr. Lequn HuangChairman of the Board, since 2020
- Mr. Qun ZhaoPresident, Director, since 2010CN¥891,900
- Mr. Hairong ZhongVice Chairman of the Board, since 2015
- Mr. Yanjie HeChief Financial Officer
- Mr. Junxian YuVice President, Secretary of the Board, DirectorCN¥448,200
- Mr. Kairui LuoVice President
- Ms. Han YinVice President
- Mr. Yingmin YuChief Engineer
- Mr. Hao GaoIndependent Director, since 2020
- Mr. Tao JuIndependent Director
- Mr. Zhukun LouIndependent Director
- Mr. Guohua YuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanxi C&Y Pharmaceutical Group Co Ltd possesses several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company benefits from a strong reputation for producing high-quality pharmaceutical products. This reputation has been built through years of experience and consistent adherence to strict quality control standards. Secondly, C&Y Pharmaceutical Group has a wide range of product offerings, including both traditional medicine and modern drugs, which enables the company to cater to a diverse customer base and capture a larger market share. Furthermore, the company has established strong relationships with key stakeholders, including suppliers, distributors, and healthcare professionals, which enhances its distribution network and market reach.
Weaknesses
- Despite its strengths, Shanxi C&Y Pharmaceutical Group Co Ltd also faces certain weaknesses that can hinder its performance. One notable weakness is the company's limited international presence and reliance on the domestic market. This dependence on a single market exposes C&Y Pharmaceutical Group to the risks associated with fluctuations in the domestic economy. Additionally, the company may face challenges related to regulatory compliance and intellectual property protection, which could impact its ability to expand into new markets and protect its innovations.
Opportunities
- The pharmaceutical industry presents several opportunities for Shanxi C&Y Pharmaceutical Group Co Ltd. Firstly, as the demand for healthcare products and services continues to rise globally, especially in emerging markets, the company can capitalize on this growth by expanding its international presence and penetrating new markets. Moreover, advancements in research and development technology provide C&Y Pharmaceutical Group with opportunities to innovate and develop new drugs and therapies, which can enhance its competitive advantage. Additionally, the increasing focus on preventive healthcare and alternative medicine opens doors for the company to expand its product portfolio and cater to a broader range of customer needs.
Threats
- Shanxi C&Y Pharmaceutical Group Co Ltd faces various threats that could pose challenges to its operations. One significant threat is intense competition within the pharmaceutical industry, with numerous domestic and international players. This competition can lead to price pressure and market saturation, making it crucial for the company to differentiate itself effectively. Additionally, regulatory changes and government policies can impact the company's operations and profitability, necessitating continuous monitoring and adaptation to comply with evolving regulations. Furthermore, the risk of product counterfeit and intellectual property infringement presents threats to the company's reputation, customer trust, and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.